病例报告:在与他类药物相关的神经病变中,白细胞基因表达的运动相关变化
Galyna Bondar1, Abhinandan Das Mahapatra2, Irina Silacheva1
1David Geffen School of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA, United States.
Frontiers in pharmacology
|December 22, 2025
概括
这项研究使用转录学揭示了在他类药物相关肌肉症状 (SAMS) 期间免疫系统的变化. 运动挑战突出显示了免疫基因表达的改变,这表明SAMS的免疫成分.
科学领域:
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
- 运动生理学 运动生理学
背景情况:
- 类他类药物相关的肌肉症状 (SAMS) 是一种常见的临床问题,原因不明.
- 免疫因素在SAMS中被怀疑但未得到证实.
- 这项研究使用纵向转录基因方法研究SAMS期间免疫基因表达的变化.
研究的目的:
- 在他类药物相关肌肉症状 (SAMS) 期间,探索外围血液单核细胞 (PBMC) 中免疫相关基因表达变化.
- 通过转录基因分析识别SAMS的潜在免疫机制.
- 评估免疫转录组在运动前,运动期间和运动后对免疫转录组的动态变化.
主要方法:
- 一名健康的志愿者接受了心肺运动测试 (CPX) 在三个时间点:基线,SAMS期间和部分恢复期间.
- 用下一代RNA测序收集和分析了周围血液单核细胞 (PBMC).
- 差异基因表达分析,加权基因共同表达网络分析 (WGCNA) 和途径/基因本体学丰富用于识别免疫特征.
主要成果:
- 与基线和恢复相比,SAMS期间观察到PBMC基因表达特征的明显变化.
- WGCNA确定了39个共同表达模块,其中几个显示了在SAMS期间与炼相关的改变表达模式.
- 基因本体学和Reactome分析突出了16个在运动高峰时差异表达的基因,可能与SAMS病变发生有关.
结论:
- 剖析运动诱导的免疫转录组可以揭示与他类药物诱导肌肉病相关的动态免疫变化.
- 这些发现支持SAMS中免疫介导成分的假设.
- 这项研究为开发用于SAMS检测和管理的转录基因生物标志物提供了基础.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...